| Year |
Citation |
Score |
| 2021 |
Failli V, Kleitman N, Lammertse DP, Hsieh JTC, Steeves JD, Fawcett JW, Tuszynski MH, Curt A, Fehlings MG, Guest JD, Blight AR. Experimental Treatments for Spinal Cord Injury: What you Should Know. Topics in Spinal Cord Injury Rehabilitation. 27: 50-74. PMID 34108834 DOI: 10.46292/sci2702-50 |
0.412 |
|
| 2020 |
Mulcahey MJ, Jones LAT, Rockhold F, Rupp R, Kramer JLK, Kirshblum S, Blight A, Lammertse D, Guest JD, Steeves JD. Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system. Spinal Cord. PMID 32939028 DOI: 10.1038/S41393-020-00547-8 |
0.501 |
|
| 2019 |
Rosenzweig ES, Salegio EA, Liang JJ, Weber JL, Weinholtz CA, Brock JH, Moseanko R, Hawbecker S, Pender R, Cruzen CL, Iaci JF, Caggiano AO, Blight AR, Haenzi B, Huie JR, et al. Chondroitinase improves anatomical and functional outcomes after primate spinal cord injury. Nature Neuroscience. PMID 31235933 DOI: 10.1038/S41593-019-0424-1 |
0.521 |
|
| 2019 |
Blight AR, Hsieh J, Curt A, Fawcett JW, Guest JD, Kleitman N, Kurpad SN, Kwon BK, Lammertse DP, Weidner N, Steeves JD. The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury. Spinal Cord. PMID 30962518 DOI: 10.1038/S41393-019-0276-2 |
0.53 |
|
| 2018 |
Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. Cns Drugs. PMID 30535670 DOI: 10.1007/S40263-018-0586-5 |
0.324 |
|
| 2018 |
Bolliger M, Blight AR, Field-Fote EC, Musselman K, Rossignol S, Barthélemy D, Bouyer L, Popovic MR, Schwab JM, Boninger ML, Tansey KE, Scivoletto G, Kleitman N, Jones LAT, Gagnon DH, et al. Lower extremity outcome measures: considerations for clinical trials in spinal cord injury. Spinal Cord. PMID 29700477 DOI: 10.1038/S41393-018-0097-8 |
0.505 |
|
| 2018 |
Steeves J, Curt A, Mehra M, Rupp R, Blight A, Maier D, Jones L, Lammertse D, Abel R, Kirshblum S, Weidner N. The Spinal Cord Ability Ruler (SCAR) complements the Spinal Cord Independence Measure (SCIM). Spinal Cord. PMID 29386658 DOI: 10.1038/S41393-018-0064-4 |
0.458 |
|
| 2017 |
Jones LAT, Bryden A, Wheeler TL, Tansey KE, Anderson KD, Beattie MS, Blight A, Curt A, Field-Fote E, Guest JD, Hseih J, Jakeman LB, Kalsi-Ryan S, Krisa L, Lammertse DP, et al. Considerations and recommendations for selection and utilization of upper extremity clinical outcome assessments in human spinal cord injury trials. Spinal Cord. PMID 29284795 DOI: 10.1038/S41393-017-0015-5 |
0.494 |
|
| 2017 |
Reed R, Mehra M, Kirshblum S, Maier D, Lammertse D, Blight A, Rupp R, Jones L, Abel R, Weidner N, Curt A, Steeves J. Spinal cord ability ruler: an interval scale to measure volitional performance after spinal cord injury. Spinal Cord. PMID 28322239 DOI: 10.1038/Sc.2017.1 |
0.494 |
|
| 2017 |
Moore SA, Granger N, Olby N, Spitzbarth I, Jeffery ND, Tipold A, Nout-Lomas YS, da Costa R, Stein V, Noble-Haeusslein L, Blight AR, Grossman R, Basso DM, Levine JM. Targeting translational successes through CANSORT-SCI: using pet dogs to identify effective treatments for spinal cord injury. Journal of Neurotrauma. PMID 28230415 DOI: 10.1089/neu.2016.4745 |
0.406 |
|
| 2015 |
Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ. Effects of Dalfampridine Extended-Release Tablets on 6-Minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial. Clinical Therapeutics. PMID 26565077 DOI: 10.1016/J.Clinthera.2015.10.014 |
0.365 |
|
| 2015 |
Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR, Blight AR, Carrazana EJ. Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. International Journal of Ms Care. 17: 138-45. PMID 26052259 DOI: 10.7224/1537-2073.2014-040 |
0.319 |
|
| 2015 |
Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 25583832 DOI: 10.1177/1352458514563591 |
0.352 |
|
| 2015 |
Wu X, Liu J, Tanadini LG, Lammertse DP, Blight AR, Kramer JL, Scivoletto G, Jones L, Kirshblum S, Abel R, Fawcett J, Field-Fote E, Guest J, Levinson B, Maier D, et al. Challenges for defining minimal clinically important difference (MCID) after spinal cord injury. Spinal Cord. 53: 84-91. PMID 25510192 DOI: 10.1038/Sc.2014.232 |
0.5 |
|
| 2014 |
Goodman AD, Brown TR, Schapiro RT, Klingler M, Cohen R, Blight AR. A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. International Journal of Ms Care. 16: 153-60. PMID 25337058 DOI: 10.7224/1537-2073.2013-023 |
0.353 |
|
| 2014 |
Blight AR, Henney HR, Cohen R. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Annals of the New York Academy of Sciences. 1329: 33-44. PMID 25154911 DOI: 10.1111/Nyas.12512 |
0.36 |
|
| 2014 |
Yates JR, Gay EA, Heyes MP, Blight AR. Effects of methylprednisolone and 4-chloro-3-hydroxyanthranilic acid in experimental spinal cord injury in the guinea pig appear to be mediated by different and potentially complementary mechanisms. Spinal Cord. 52: 662-6. PMID 25047053 DOI: 10.1038/Sc.2014.118 |
0.492 |
|
| 2014 |
Cardenas DD, Ditunno JF, Graziani V, McLain AB, Lammertse DP, Potter PJ, Alexander MS, Cohen R, Blight AR. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury. Spinal Cord. 52: 70-6. PMID 24216616 DOI: 10.1038/Sc.2013.137 |
0.508 |
|
| 2013 |
Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 80: 1509-17. PMID 23535489 DOI: 10.1212/Wnl.0B013E31828Cf7F3 |
0.318 |
|
| 2012 |
Steeves JD, Lammertse DP, Kramer JL, Kleitman N, Kalsi-Ryan S, Jones L, Curt A, Blight AR, Anderson KD. Outcome Measures for Acute/Subacute Cervical Sensorimotor Complete (AIS-A) Spinal Cord Injury During a Phase 2 Clinical Trial. Topics in Spinal Cord Injury Rehabilitation. 18: 1-14. PMID 23239927 DOI: 10.1310/Sci1801-1 |
0.515 |
|
| 2012 |
Steeves J, Blight A. Spinal cord injury clinical trials translational process, review of past and proposed acute trials with reference to recommended trial guidelines. Handbook of Clinical Neurology. 109: 386-98. PMID 23098726 DOI: 10.1016/B978-0-444-52137-8.00024-3 |
0.483 |
|
| 2012 |
Cornblath DR, Bienen EJ, Blight AR. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clinical Therapeutics. 34: 1056-69. PMID 22497693 DOI: 10.1016/J.Clinthera.2012.03.007 |
0.341 |
|
| 2011 |
Blight AR. Treatment of walking impairment in multiple sclerosis with dalfampridine. Therapeutic Advances in Neurological Disorders. 4: 99-109. PMID 21694807 DOI: 10.1177/1756285611403960 |
0.392 |
|
| 2011 |
Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Current Medical Research and Opinion. 27: 1415-1423. PMID 21595605 DOI: 10.1185/03007995.2011.583229 |
0.333 |
|
| 2011 |
Zariffa J, Kramer JL, Fawcett JW, Lammertse DP, Blight AR, Guest J, Jones L, Burns S, Schubert M, Bolliger M, Curt A, Steeves JD. Characterization of neurological recovery following traumatic sensorimotor complete thoracic spinal cord injury. Spinal Cord. 49: 463-71. PMID 20938451 DOI: 10.1038/Sc.2010.140 |
0.482 |
|
| 2011 |
Steeves JD, Kramer JK, Fawcett JW, Cragg J, Lammertse DP, Blight AR, Marino RJ, Ditunno JF, Coleman WP, Geisler FH, Guest J, Jones L, Burns S, Schubert M, van Hedel HJ, et al. Extent of spontaneous motor recovery after traumatic cervical sensorimotor complete spinal cord injury. Spinal Cord. 49: 257-65. PMID 20714334 DOI: 10.1038/Sc.2010.99 |
0.401 |
|
| 2011 |
Kwon BK, Okon EB, Tsai E, Beattie MS, Bresnahan JC, Magnuson DK, Reier PJ, McTigue DM, Popovich PG, Blight AR, Oudega M, Guest JD, Weaver LC, Fehlings MG, Tetzlaff W. A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury. Journal of Neurotrauma. 28: 1525-43. PMID 20507235 DOI: 10.1089/Neu.2010.1296 |
0.458 |
|
| 2010 |
Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of Neurology. 68: 494-502. PMID 20976768 DOI: 10.1002/Ana.22240 |
0.377 |
|
| 2009 |
Vollmer T, Blight AR, Henney HR. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clinical Therapeutics. 31: 2215-23. PMID 19922892 DOI: 10.1016/J.Clinthera.2009.10.007 |
0.335 |
|
| 2009 |
Blight A, Curt A, Ditunno JF, Dobkin B, Ellaway P, Fawcett J, Fehlings M, Grossman RG, Lammertse DP, Privat A, Steeves J, Tuszynski M, Kalichman M, Guest JD. Position statement on the sale of unproven cellular therapies for spinal cord injury: the international campaign for cures of spinal cord injury paralysis. Spinal Cord. 47: 713-4. PMID 19417762 DOI: 10.1038/Sc.2008.179 |
0.493 |
|
| 2009 |
Alexander MS, Anderson KD, Biering-Sorensen F, Blight AR, Brannon R, Bryce TN, Creasey G, Catz A, Curt A, Donovan W, Ditunno J, Ellaway P, Finnerup NB, Graves DE, Haynes BA, et al. Outcome measures in spinal cord injury: recent assessments and recommendations for future directions. Spinal Cord. 47: 582-91. PMID 19381157 DOI: 10.1038/Sc.2009.18 |
0.466 |
|
| 2009 |
Blight AR, Henney HR. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clinical Therapeutics. 31: 328-35. PMID 19302905 DOI: 10.1016/J.Clinthera.2009.02.004 |
0.476 |
|
| 2009 |
Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet (London, England). 373: 732-8. PMID 19249634 DOI: 10.1016/S0140-6736(09)60442-6 |
0.391 |
|
| 2008 |
Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 71: 1134-41. PMID 18672472 DOI: 10.1212/01.Wnl.0000326213.89576.0E |
0.364 |
|
| 2007 |
Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR. Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study Multiple Sclerosis. 13: 357-368. PMID 17439905 DOI: 10.1177/1352458506069538 |
0.333 |
|
| 2007 |
Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D, Bartlett PF, Blight AR, Dietz V, Ditunno J, Dobkin BH, Havton LA, Ellaway PH, Fehlings MG, Privat A, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord. 45: 190-205. PMID 17179973 DOI: 10.1038/Sj.Sc.3102007 |
0.536 |
|
| 2007 |
Steeves JD, Lammertse D, Curt A, Fawcett JW, Tuszynski MH, Ditunno JF, Ellaway PH, Fehlings MG, Guest JD, Kleitman N, Bartlett PF, Blight AR, Dietz V, Dobkin BH, Grossman R, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord. 45: 206-21. PMID 17179972 DOI: 10.1038/Sj.Sc.3102008 |
0.466 |
|
| 2007 |
Tuszynski MH, Steeves JD, Fawcett JW, Lammertse D, Kalichman M, Rask C, Curt A, Ditunno JF, Fehlings MG, Guest JD, Ellaway PH, Kleitman N, Bartlett PF, Blight AR, Dietz V, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord. 45: 222-31. PMID 17179971 DOI: 10.1038/Sj.Sc.3102009 |
0.492 |
|
| 2007 |
Lammertse D, Tuszynski MH, Steeves JD, Curt A, Fawcett JW, Rask C, Ditunno JF, Fehlings MG, Guest JD, Ellaway PH, Kleitman N, Blight AR, Dobkin BH, Grossman R, Katoh H, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord. 45: 232-42. PMID 17179970 DOI: 10.1038/Sj.Sc.3102010 |
0.457 |
|
| 2007 |
Cardenas DD, Ditunno J, Graziani V, Jackson AB, Lammertse D, Potter P, Sipski M, Cohen R, Blight AR. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 45: 158-68. PMID 16773037 DOI: 10.1038/Sj.Sc.3101947 |
0.467 |
|
| 2006 |
Yates JR, Heyes MP, Blight AR. 4-chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery, and preserves white matter after spinal cord injury. Journal of Neurotrauma. 23: 866-81. PMID 16774472 DOI: 10.1089/Neu.2006.23.866 |
0.5 |
|
| 2006 |
Blight AR, Tuszynski MH. Clinical trials in spinal cord injury. Journal of Neurotrauma. 23: 586-93. PMID 16629639 DOI: 10.1089/Neu.2006.23.586 |
0.509 |
|
| 2005 |
Caggiano AO, Zimber MP, Ganguly A, Blight AR, Gruskin EA. Chondroitinase ABCI improves locomotion and bladder function following contusion injury of the rat spinal cord. Journal of Neurotrauma. 22: 226-39. PMID 15716629 DOI: 10.1089/Neu.2005.22.226 |
0.521 |
|
| 2004 |
Blight AR. Just one word: plasticity. Nature Neuroscience. 7: 206-8. PMID 14983180 DOI: 10.1038/Nn0304-206 |
0.454 |
|
| 2004 |
Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Archives of Physical Medicine and Rehabilitation. 85: 29-34. PMID 14970964 DOI: 10.1016/S0003-9993(03)00651-8 |
0.511 |
|
| 2003 |
Hayes KC, Potter PJ, Hansebout RR, Bugaresti JM, Hsieh JT, Nicosia S, Katz MA, Blight AR, Cohen R. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. Clinical Neuropharmacology. 26: 185-92. PMID 12897638 DOI: 10.1097/00002826-200307000-00007 |
0.454 |
|
| 2003 |
Hayes KC, Katz MA, Devane JG, Hsieh JTC, Wolfe DL, Potter PJ, Blight AR. Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury Journal of Clinical Pharmacology. 43: 379-385. PMID 12723458 DOI: 10.1177/0091270003251388 |
0.452 |
|
| 2002 |
Blight AR. Miracles and molecules--progress in spinal cord repair. Nature Neuroscience. 5: 1051-4. PMID 12403984 DOI: 10.1038/Nn939 |
0.513 |
|
| 2001 |
Blight AR, Zimber MP. Acute spinal cord injury: pharmacotherapy and drug development perspectives. Current Opinion in Investigational Drugs (London, England : 2000). 2: 801-8. PMID 11572660 |
0.427 |
|
| 2000 |
Halter JA, Blight AR, Donovan WH, Calvillo O. Intrathecal administration of 4-aminopyridine in chronic spinal injured patients. Spinal Cord. 38: 728-32. PMID 11175372 DOI: 10.1038/Sj.Sc.3101098 |
0.433 |
|
| 2000 |
Shi R, Asano T, Vining NC, Blight AR. Control of membrane sealing in injured mammalian spinal cord axons Journal of Neurophysiology. 84: 1763-1769. PMID 11024068 DOI: 10.1152/Jn.2000.84.4.1763 |
0.368 |
|
| 2000 |
Donovan WH, Halter JA, Graves DE, Blight AR, Calvillo O, McCann MT, Sherwood AM, Castillo T, Parsons KC, Strayer JR. Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord. 38: 7-15. PMID 10762192 DOI: 10.1038/Sj.Sc.3100931 |
0.459 |
|
| 2000 |
Blight AR. Animal models of spinal cord injury Topics in Spinal Cord Injury Rehabilitation. 6: 1-13. DOI: 10.1310/2Xny-A824-Uctf-En4D |
0.486 |
|
| 1999 |
LoPachin RM, Gaughan CL, Lehning EJ, Kaneko Y, Kelly TM, Blight A. Experimental spinal cord injury: spatiotemporal characterization of elemental concentrations and water contents in axons and neuroglia. Journal of Neurophysiology. 82: 2143-53. PMID 10561394 DOI: 10.1152/Jn.1999.82.5.2143 |
0.438 |
|
| 1999 |
Shi R, Borgens RB, Blight AR. Functional reconnection of severed mammalian spinal cord axons with polyethylene glycol. Journal of Neurotrauma. 16: 727-38. PMID 10511246 DOI: 10.1089/Neu.1999.16.727 |
0.314 |
|
| 1999 |
Bell MJ, Kochanek PM, Heyes MP, Wisniewski SR, Sinz EH, Clark RS, Blight AR, Marion DW, Adelson PD. Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury. Critical Care Medicine. 27: 493-7. PMID 10199527 DOI: 10.1097/00003246-199903000-00023 |
0.301 |
|
| 1998 |
Sinz EH, Kochanek PM, Heyes MP, Wisniewski SR, Bell MJ, Clark RS, DeKosky ST, Blight AR, Marion DW. Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 18: 610-5. PMID 9626184 DOI: 10.1097/00004647-199806000-00002 |
0.328 |
|
| 1997 |
Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord Neuroscience. 77: 553-562. PMID 9472411 DOI: 10.1016/S0306-4522(96)00477-0 |
0.456 |
|
| 1997 |
Shi R, Kelly TM, Blight AR. Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. Experimental Neurology. 148: 495-501. PMID 9417828 DOI: 10.1006/Exnr.1997.6706 |
0.455 |
|
| 1997 |
Jaeger CB, Blight AR. Spinal cord compression injury in guinea pigs: Structural changes of endothelium and its perivascular cell associations after blood-brain barrier breakdown and repair Experimental Neurology. 144: 381-399. PMID 9168838 DOI: 10.1006/Exnr.1996.6405 |
0.345 |
|
| 1997 |
Blight AR, Leroy EC, Heyes MP. Quinolinic acid accumulation in injured spinal cord: Time course, distribution, and species differences between rat and guinea pig Journal of Neurotrauma. 14: 89-98. PMID 9069440 DOI: 10.1089/Neu.1997.14.89 |
0.453 |
|
| 1997 |
Podhajsky RJ, Bidanset DJ, Caterson B, Blight AR. A quantitative immunohistochemical study of the cellular response to crush injury in optic nerve Experimental Neurology. 143: 153-161. PMID 9000454 DOI: 10.1006/Exnr.1996.6354 |
0.365 |
|
| 1997 |
Sinz EH, Kochanek PM, Heyes MP, Bell M, Wisniewski S, Clark RS, DeKosky ST, Blight AR, Marion DW. Quinolinic Acid Is Increased In Csf And Associated With Mortality In Human Head Injury Journal of Neurosurgical Anesthesiology. 9: 379. DOI: 10.1097/00008506-199710000-00018 |
0.305 |
|
| 1997 |
Fessler R, Quencer R, Hall E, Tessier-Lavigne M, McKerracher L, Kocsis J, Reier P, Snyder E, Bregman B, Edgerton R, Calancie B, Trull FL, Cardenas D, DeLisa J, Whiteneck G, ... Blight AR, et al. Abstracts from the Spinal Cord Research Foundation’s 20th Anniversary Symposium The Journal of Spinal Cord Medicine. 20: 90-100. DOI: 10.1080/10790268.1997.11719462 |
0.425 |
|
| 1996 |
Shi R, Blight AR. Compression injury of mammalian spinal cord in vitro and the dynamics of action potential conduction failure Journal of Neurophysiology. 76: 1572-1580. PMID 8890277 DOI: 10.1152/Jn.1996.76.3.1572 |
0.423 |
|
| 1996 |
Gruner JA, Yee AK, Blight AR. Histological and functional evaluation of experimental spinal cord injury: Evidence of a stepwise response to graded compression Brain Research. 729: 90-101. PMID 8874880 DOI: 10.1016/0006-8993(96)00366-6 |
0.477 |
|
| 1996 |
Cohen TI, Weinberg RJ, Blight AR. Intrathecal infusion of the nitric oxide synthase inhibitor N-methyl L-arginine after experimental spinal cord injury in guinea pigs. Journal of Neurotrauma. 13: 361-9. PMID 8863192 DOI: 10.1089/Neu.1996.13.361 |
0.453 |
|
| 1995 |
Blight AR, Cohen TI, Saito K, Heyes MP. Quinolinic acid accumulation and functional deficits following experimental spinal cord injury Brain. 118: 735-752. PMID 7600090 DOI: 10.1093/Brain/118.3.735 |
0.515 |
|
| 1994 |
Blight AR. Effects of silica on the outcome from experimental spinal cord injury: Implication of macrophages in secondary tissue damage Neuroscience. 60: 263-273. PMID 8052418 DOI: 10.1016/0306-4522(94)90220-8 |
0.337 |
|
| 1994 |
Hayes KC, Potter PJ, Wolfe DL, Hsieh JTC, Delaney GA, Blight AR. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury Journal of Neurotrauma. 11: 433-446. PMID 7837283 DOI: 10.1089/Neu.1994.11.433 |
0.472 |
|
| 1993 |
Borgens RB, Blight AR. Delayed application of direct current electric fields in experimental spinal cord injuries. Restorative Neurology and Neuroscience. 5: 173-9. PMID 21551899 DOI: 10.3233/RNN-1993-5301 |
0.342 |
|
| 1993 |
Borgens RB, Toombs JP, Blight AR, McGinnis ME, Bauer MS, Widmer WR, Cook JR. Effects of applied electric fields on clinical cases of complete paraplegia in dogs. Restorative Neurology and Neuroscience. 5: 305-22. PMID 21551717 DOI: 10.3233/RNN-1993-55601 |
0.335 |
|
| 1993 |
Hayes KC, Blight AR, Potter PJ, Allatt RD, Hsieh JTC, Wolfe DL, Lam S, Hamilton JT. Predinical trial of 4-aminopyridine in patients with chronic spinal cord injury Paraplegia. 31: 216-224. PMID 8493036 DOI: 10.1038/Sc.1993.40 |
0.541 |
|
| 1993 |
Blight AR. Remyelination, revascularization, and recovery of function in experimental spinal cord injury Advances in Neurology. 59: 91-104. PMID 8420127 |
0.417 |
|
| 1993 |
Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: A controlled, double- blind, crossover study in eight patients Journal of Neurotrauma. 10: 1-18. PMID 8320728 DOI: 10.1089/Neu.1993.10.1 |
0.486 |
|
| 1993 |
Hayes KC, Hsieh JTC, Potter PJ, Wolfe DL, Delaney GA, Blight AR. Effects of induced hypothermia on somatosensory evoked potentials in patients with chronic spinal cord injury Paraplegia. 31: 730-741. PMID 8295782 DOI: 10.1038/sc.1993.115 |
0.34 |
|
| 1993 |
Blight AR, Saito K, Heyes MP. Increased levels of the excitotoxin quinolinic acid in spinal cord following contusion injury Brain Research. 632: 314-316. PMID 8149236 DOI: 10.1016/0006-8993(93)91167-Q |
0.502 |
|
| 1992 |
Blight AR. Macrophages and inflammatory damage in spinal cord injury Journal of Neurotrauma. 9. PMID 1588634 |
0.339 |
|
| 1992 |
Blight AR. Spinal cord injury models: Neurophysiology Journal of Neurotrauma. 9: 147-150. PMID 1404430 |
0.412 |
|
| 1991 |
Blight AR. Morphometric analysis of a model of spinal cord injury in guinea pigs, with behavioral evidence of delayed secondary pathology Journal of the Neurological Sciences. 103: 156-171. PMID 1880533 DOI: 10.1016/0022-510X(91)90159-5 |
0.389 |
|
| 1991 |
Blight AR, Toombs JP, Bauer MS, Widmer WR. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: A phase I clinical trial Journal of Neurotrauma. 8: 103-119. PMID 1870134 |
0.415 |
|
| 1991 |
Blight AR. Morphometric analysis of blood vessels in chronic experimental spinal cord injury: Hypervascularity and recovery of function Journal of the Neurological Sciences. 106: 158-174. PMID 1802964 DOI: 10.1016/0022-510X(91)90253-4 |
0.401 |
|
| 1989 |
Blight AR, Young W. Central axons in injured cat spinal cord recover electrophysiological function following remyelination by Schwann cells Journal of the Neurological Sciences. 91: 15-34. PMID 2746287 DOI: 10.1016/0022-510X(89)90073-7 |
0.324 |
|
| 1989 |
Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury Brain Research Bulletin. 22: 47-52. PMID 2540887 DOI: 10.1016/0361-9230(89)90126-3 |
0.342 |
|
| 1988 |
Young W, DeCrescito V, Flamm ES, Blight AR, Gruner JA. Pharmacological therapy of acute spinal cord injury: studies of high dose methylprednisolone and naloxone Clinical Neurosurgery. 34: 675-697. PMID 3378379 |
0.404 |
|
| 1987 |
Borgens RB, Blight AR, McGinnis ME. Behavioral recovery induced by applied electric fields after spinal cord hemisection in guinea pig. Science (New York, N.Y.). 238: 366-9. PMID 3659920 DOI: 10.1126/Science.3659920 |
0.308 |
|
| 1987 |
Blight AR, Gruner JA. Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats Journal of the Neurological Sciences. 82: 145-159. PMID 2831307 DOI: 10.1016/0022-510X(87)90014-1 |
0.413 |
|
| 1986 |
Ridella SA, Anderson TE, Blight AR. Compression of rat spinal cord in vitro: Effects of ethanol on recovery of axonal conduction Central Nervous System Trauma. 3: 193-205. PMID 3802222 |
0.305 |
|
| 1986 |
Blight AR, Decrescito V. Morphometric analysis of experimental spinal cord injury in the cat: The relation of injury intensity to survival of myelinated axons Neuroscience. 19: 321-341. PMID 3785669 DOI: 10.1016/0306-4522(86)90025-4 |
0.377 |
|
| 1985 |
Blight AR. Delayed demyelination and macrophage invasion: A candidate for secondary cell damage in spinal cord injury Central Nervous System Trauma. 2: 299-315. PMID 3836014 |
0.393 |
|
| 1983 |
Blight AR. Cellular morphology of chronic spinal cord injury in the cat: Analysis of myelinated axons by line-sampling Neuroscience. 10. PMID 6633870 DOI: 10.1016/0306-4522(83)90150-1 |
0.33 |
|
| 1982 |
Blight AR, Precht W. Miniature synaptic potentials absent from motoneurons of intact spinal cord. Brain Research. 238: 228-32. PMID 6123372 DOI: 10.1016/0006-8993(82)90788-0 |
0.328 |
|
| Show low-probability matches. |